Will Clovis’ Rubraca sales shortfall revive talk of a buyout at JP Morgan?

At last year's J.P. Morgan Healthcare Conference, Clovis CEO Patrick Mahaffy suggested he'd take any buyout offers for his company seriously. A year later, the company's stock is way down on a disappointing performance from its sole product, the PARP inhibitor Rubraca to treat ovarian cancer. That could push Clovis to the top of the M&A target list again.